Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4161 participants.
Also called NCT01508026
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,161 participants
- Sponsor
- Registry
-
NCT01508026
-
- Other papers using this trial's data
- Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01508026. Randomized; triple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
- Condition
- Stage 1 Hypertension
- Condition
- Stage 2 Hypertension
- Intervention (Drug)
- Nebivolol and Valsartan 1
- Intervention (Drug)
- Nebivolol and Valsartan 2
- Intervention (Drug)
- Nebivolol and Valsartan 3
- Intervention (Drug)
- Nebivolol 1
- Intervention (Drug)
- Nebivolol 2
- Intervention (Drug)
- Valsartan 1
- Intervention (Drug)
- Valsartan 2
- Intervention (Drug)
- Placebo
- Lead sponsor
- Forest Laboratories
Record details
- Record id
cardio:ct-nct01508026- Content hash
5bc28858d2f5990941f1d1858375846749e43dc1a3c68c357db3089a02ab5f6b